HomeCompareAKYA vs MRK

AKYA vs MRK: Dividend Comparison 2026

AKYA yields 155.04% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKYA wins by $29.53M in total portfolio value
10 years
AKYA
AKYA
● Live price
155.04%
Share price
$1.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.59M
Annual income
$13,040,704.30
Full AKYA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — AKYA vs MRK

📍 AKYA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKYAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKYA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKYA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKYA
Annual income on $10K today (after 15% tax)
$13,178.29/yr
After 10yr DRIP, annual income (after tax)
$11,084,598.66/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, AKYA beats the other by $11,076,270.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKYA + MRK for your $10,000?

AKYA: 50%MRK: 50%
100% MRK50/50100% AKYA
Portfolio after 10yr
$14.82M
Annual income
$6,525,251.22/yr
Blended yield
44.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AKYA
Analyst Ratings
2
Buy
7
Hold
Consensus: Hold
Price Target
$4.98
+286.0% upside vs current
Range: $2.40 — $7.50
Altman Z
-4.2
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKYA buys
0
MRK buys
0
No recent congressional trades found for AKYA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKYAMRK
Forward yield155.04%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$29.59M$56.8K
Annual income after 10y$13,040,704.30$9,798.13
Total dividends collected$27.44M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$4.98$128.54

Year-by-year: AKYA vs MRK ($10,000, DRIP)

YearAKYA PortfolioAKYA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$26,204$15,503.88$11,206$366.19+$15.0KAKYA
2$66,007$37,968.38$12,650$502.35+$53.4KAKYA
3$160,011$89,383.96$14,407$694.19+$145.6KAKYA
4$373,718$202,506.35$16,585$967.82+$357.1KAKYA
5$841,906$442,027.47$19,342$1,363.89+$822.6KAKYA
6$1,831,486$930,646.81$22,913$1,947.19+$1.81MAKYA
7$3,851,778$1,892,087.52$27,662$2,823.89+$3.82MAKYA
8$7,840,307$3,718,904.61$34,159$4,173.35+$7.81MAKYA
9$15,463,748$7,074,619.86$43,337$6,308.80+$15.42MAKYA
10$29,586,915$13,040,704.30$56,776$9,798.13+$29.53MAKYA

AKYA vs MRK: Complete Analysis 2026

AKYAStock

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Full AKYA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AKYA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKYA vs SCHDAKYA vs JEPIAKYA vs OAKYA vs KOAKYA vs MAINAKYA vs JNJAKYA vs ABBVAKYA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.